0001387131-21-007179.txt : 20210706 0001387131-21-007179.hdr.sgml : 20210706 20210706163814 ACCESSION NUMBER: 0001387131-21-007179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210702 FILED AS OF DATE: 20210706 DATE AS OF CHANGE: 20210706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40545 FILM NUMBER: 211074606 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CVRx, Inc. CENTRAL INDEX KEY: 0001235912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 9201 WEST BROADWAY AVENUE STREET 2: SUITE 650 CITY: MINNEAPOLIS STATE: MN ZIP: 55445 BUSINESS PHONE: 7634162850 MAIL ADDRESS: STREET 1: 9201 WEST BROADWAY AVENUE STREET 2: SUITE 650 CITY: MINNEAPOLIS STATE: MN ZIP: 55445 FORMER COMPANY: FORMER CONFORMED NAME: CVRX INC DATE OF NAME CHANGE: 20030527 4 1 cvrx-form4_070221.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP X0306 4 2021-07-02 1 0001235912 CVRx, Inc. CVRX 0001131399 GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS UNITED KINGDOM 0 0 1 0 Common Stock 2021-07-02 4 C 0 1505 A 33316 I See Footnote Common Stock 2021-07-02 4 C 0 12979 A 46295 I See Footnote Common Stock 2021-07-02 4 C 0 14917 A 61212 I See Footnote Common Stock 2021-07-02 4 C 0 8380 A 69592 I See Footnote Common Stock 2021-07-02 4 C 0 27345 A 96937 I See Footnote Common Stock 2021-07-02 4 C 0 635646 A 732583 I See Footnote Common Stock 2021-07-02 4 P 0 275000 18 A 1007583 I See Footnote Series B-2 Preferred Stock 2021-07-02 4 C 0 59527 0 D Common Stock 1505 0 I See Footnote Series C-2 Preferred Stock 2021-07-02 4 C 0 513312 0 D Common Stock 12979 0 I See Footnote Series D-2 Preferred Stock 2021-07-02 4 C 0 589939 0 D Common Stock 14917 0 I See Footnote Series E-2 Preferred Stock 2021-07-02 4 C 0 331399 0 D Common Stock 8380 0 I See Footnote Series F-2 Preferred Stock 2021-07-02 4 C 0 1081434 0 D Common Stock 27345 0 I See Footnote Series G Preferred Stock 2021-07-02 4 C 0 10055408 0 D Common Stock 635646 0 I See Footnote Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering. The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person. /s/ Victoria Whyte 2021-07-06